Ohashi, K., L. V. Sequist, M. E. Arcila, C. M. Lovly, X. Chen, C. M. Rudin, T. Moran, D. R. Camidge, C. L. Vnencak-Jones, L. Berry, Y. Pan, H. Sasaki, J. A. Engelmann, E. B. Garon, S. M. Dubinett, W. A. Franklin, G. J. Riely, M. L. Sos, M. G. Kris, D. Dias-Santagata, M. Ladanyi, P. A. Bunn and W. Pao: Characteristics of lung cancers harboring NRAS mutations. In: Clinical Cancer Research 19, 9, 2584-2591 (2013).
doi: 10.1158/1078-0432.CCR-12-3173
Ohashi, K., L. V. Sequist, T. Moran, J. Chmielecki, Y.-L. Lin, Y. Pan, L. Wang, E. de Stanchina, K. Shien, K. Aoe, S. Toyooka, K. Kiura, L. Fernandez-Cuesta, P. Fidias, J. C.-H. Yang, V. A. Miller, G. J. Riely, M. G. Kris, J. A. Engelman, X. L. Vnencak-Jones, D. Dias-Santagata, M. Ladanyi and W. Pao: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. In: Proceedings of the National Academy of Sciences of the United States of America 109, 31, E2127-E2133 (2012).
doi: 10.1073/pnas.1203530109
http://edoc.mpg.de
The Max Planck Society does not take any responsibility for the content of this export.